巨和粒治疗恶性肿瘤患者化疗后血小板减少症的临床观察

目的：观察重组人白细胞介素-11（巨和粒）治疗恶性肿瘤患者化疗后血小板减少的疗效和不良反应。方法：36例化疗后血小板减少的恶性肿瘤患者分为两组，A组（治疗组）19例使用巨和粒皮下注射1．5mg／d，连用5～12d；B组（空白对照组）17例只使用一般补血和提升血小板计数的普通药物。每周观察巨和粒对血小板计数的影响，连续观察3周。结果：化疗结束后A组血小板计数[（42．00±12．29）×10^9／L]明显低于化疗前[（192．00±73．56）×10^9／L]（P〈0．05），B组血小板计数[（44．58±11．74）×10^9／L]亦明显低于化疗前[（203．37±75．28）×10^9／L（P〈0．05）。A组治疗1周和2周后血小板恢复正常水平的比例（42．11％、100．00％）均明显高于B组（0、11．76％），差异有统计学意义（P〈0．01）。A组19例患者未出现明显恶心、呕吐、腹泻等不良反应，患者耐受性良好，未发生严重不良反应和不良事件。结论：巨和粒治疗恶性肿瘤化疗后血小板减少安全、有效，不良反应少，患者可以耐受。

Effects of treatment of chemotherapy-induced thrombocytopenia in patients of carcinoma with recombinant human interleukin-11

Objective:To investigate the effects of treatment of chemotherapy-induced thrombocytopenia in patients of carcinoma with recombinant human interleukin-11(rhIL-11). Methods:Thirty-six patients of carcinoma with chemotherapy-induced thrombocytopenia were divided into two groups:group A (19 cases) and group B (17 cases). Patients of group A were treated with rhIL-11,1.5mg daily,injected hypodermicly for 5 ~12 days ; patients of group B were treated with conventional regime. Platelet count was observed weekly for three weeks. Results:Platelet count in group A and B were(42.00±12.29)×109 L-1 ,(44.58±11.74)×109 L-1 and (192.00±73.56)×109 L-1,(203.37±75.28)×109 L-1 after and before chemotherapy respectively,compared them with those before chemotherapy ,all decreased after chemotherapy (P<0.05). After therapy,platelet count increased and gradually recovered to normal level,the normalization rates of platelet count in group A and B were 42.11% ,0 % and 100.00%,11.76% in the first and second week respectively,the differences between them were significant (P﹤0.01). Patients of group A tolerated well,no obvious nausea,vomiting,diarrhea and other adverse reactions took place. Conclusion:Treatment of chemotherapy-induced thrombocytopenia in patients of carcinoma with recombinant human interleukin-11 was safe and effective.